Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice

The safety of pirfenidone on pulmonary fibrosis patients with other kinds of interstitial lung diseases (ILDs) in addition to idiopathic pulmonary fibrosis (IPF) is unknown. Furthermore, its effectiveness-related factors on IPF patients are not quite explored. A retrospective study, on patients pres...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-01, Vol.15 (1), p.e0228390-e0228390
Main Authors: Fang, Chuling, Huang, Hui, Guo, Jian, Ferianc, Martin, Xu, Zuojun
Format: Article
Language:English
Subjects:
Aged
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Biology and Life Sciences
Biopsy
Body mass
Body Mass Index
Body size
Carbon monoxide
Carbon Monoxide - chemistry
Care and treatment
CAT scans
China
Clinical medicine
Clinical trials
Computed tomography
Connective tissue diseases
Connective tissues
Development and progression
Diffusion rate
Diseases
Drug dosages
Female
Fibrosis
Hospitals
Humans
Idiopathic Pulmonary Fibrosis - classification
Idiopathic Pulmonary Fibrosis - diagnostic imaging
Idiopathic Pulmonary Fibrosis - drug therapy
Indexing
Lung diseases
Male
Medical prognosis
Medical research
Medical schools
Medicine
Medicine and Health Sciences
Middle Aged
Nintedanib
Patients
Physical Sciences
Pirfenidone
Pulmonary fibrosis
Pyridones - administration & dosage
Pyridones - adverse effects
Research and Analysis Methods
Respiratory tract diseases
Retirement benefits
Retrospective Studies
Safety
Skin
Statistical analysis
Supervision
Tomography
Tomography, X-Ray Computed
Treatment Outcome
Tumor necrosis factor-TNF
Vital Capacity
Work experience
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The safety of pirfenidone on pulmonary fibrosis patients with other kinds of interstitial lung diseases (ILDs) in addition to idiopathic pulmonary fibrosis (IPF) is unknown. Furthermore, its effectiveness-related factors on IPF patients are not quite explored. A retrospective study, on patients prescribed pirfenidone for pulmonary fibrosis, was conducted to assess effectiveness on IPF patients and tolerability of all patients with lung fibrosis. The effectiveness of pirfenidone was tested on 110 IPF subjects receiving treatment for ≥3 months by high-resolution computed tomography (HRCT). Response-linked factors and progression-free survival (PFS) were also analyzed. The data about safety outcomes and drug dose adjustments were collected from all included subjects. A total of 176 subjects were included: 117 were IPF, 19 connective tissue disease-associated interstitial lung disease (CTD-ILD), and 40 unclassifiable ILD. Out of the 110 IPF subjects, 89 subjects were assessed as stable and 21 as progressive, out of which 10 died of acute exacerbation and 11 progressed. The effectiveness was significantly related to their baseline body mass index (BMI). IPF subjects with BMI>25kg/m2 or diffusion capacity of carbon monoxide (DLco)>30% had higher PFS rate. The most common adverse events were skin-related and gastrointestinal-related. Drug discontinuation owing to adverse events occurred similarly in these three groups. Pirfenidone was well tolerated in most of the lung fibrosis patients besides IPF, with a similar pattern of adverse events. Nearly 80% of IPF subjects were assessed as stable. More benefits were seen in IPF patients with higher BMI or mild-to-moderate disease.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0228390